Zevra Therapeutics, Inc.
ZVRA
$11.05
$0.252.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.14% | 30.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.14% | 30.93% | |||
| Cost of Revenue | 24.80% | 22.78% | |||
| Gross Profit | 5.27% | 31.34% | |||
| SG&A Expenses | 1.63% | 20.76% | |||
| Depreciation & Amortization | 0.00% | 0.32% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.39% | 13.18% | |||
| Operating Income | -5.19% | 124.84% | |||
| Income Before Tax | 253.73% | 1,396.42% | |||
| Income Tax Expenses | 1,280.04% | 215.70% | |||
| Earnings from Continuing Operations | 211.47% | 2,336.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 211.47% | 2,336.21% | |||
| EBIT | -5.19% | 124.84% | |||
| EBITDA | -4.93% | 113.38% | |||
| EPS Basic | 196.38% | 2,262.89% | |||
| Normalized Basic EPS | -10.71% | 1,238.21% | |||
| EPS Diluted | 208.01% | 2,048.00% | |||
| Normalized Diluted EPS | -9.89% | 1,193.50% | |||
| Average Basic Shares Outstanding | 3.56% | 0.80% | |||
| Average Diluted Shares Outstanding | 2.60% | 4.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||